IP Library Granted Patent US 11,821,892
Granted Patent B2
US 11,821,892 · App. 16/851,130 · Granted Nov 21, 2023

Nanobubbles

Inventors: Joseph Irudayaraj (Champaign, IL); Pushpak Bhandari (Lafayette, IN)
Assignee: Purdue Research Foundation
G01N33/5008A61K9/5047A61K31/407A61K41/00A61K41/0028A61K47/54A61K47/61A61K47/6925A61K49/223A61M37/0092A61P35/00G01N21/31A61M2210/1085G01N21/6428G01N21/6456G01N2021/6439
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,821,892
App. No.
16/851,130
Granted
Nov 21, 2023
Kind
B2
Abstract

The present invention provides oxygenized nanobubbles and their uses in imaging and cancer treatment when combined with therapeutic drugs and precise ultrasound beam steering.

Claims (6)

1. A synergistic treatment regimen for a non-muscle invasive bladder cancer (NMIBC) tumor, comprising administering synthesized oxygen nanobubbles (ONBs) to a site of bladder tumor, wherein said ONBs each comprises a gaseous molecular oxygen core surrounded by a cellulosic polymer shell, wherein said core-shell structure is capable to force a light to deviate from its linear trajectory to generate light scattering, wherein said synthesized ONBs are sized between about 400 nm to about 800 nm, the cellulosic polymer shell comprises a reaction product of a crosslinker and carboxymethyl cellulose (CMC) material, and the crosslinker has a concentration of 0.1% to 1.0%, and the carboxymethyl cellulose (CMC) material has a concentration of 0.1% to 1.0%, the ONBs further encapsulate at least one of a therapeutic drug and a florescence imaging agent, and the synthesized ONBs with drug encapsulation are guided by applying ultrasound beam and precisely steering the encapsulated drug to hypoxia regions of the NMIBC tumor.

2. The treatment regimen according to claim 1 , wherein the therapeutic drug is Mitomycin-C (MMC), and the dose of therapeutic drug (MMC) encapsulated in ONBs is reduced to about half compared to MMC treatment alone to the bladder tumor.

3. The treatment regimen according to claim 1 , wherein the ONBs travel to hypoxia regions of the bladder tumor with maximum velocity about 30 mm/s to about 40 mm/s.

4. The treatment regimen according to claim 1 , wherein the synthesized ONBs reverts hypoxia condition in said NMIBC tumors.

5. The treatment regimen for NMIBC of claim 1 , wherein said therapeutic drug is bacillus Calmette-Guerin (BCG), or mitomycin-C (MMC), and said therapeutic drug is encapsulated within said ONBs.

6. The treatment regimen for NMIBC of claim 1 , wherein the carboxymethyl cellulose (CMC) material comprises sodium carboxymethylcellulose, and the crosslinker comprises aluminum chloride.

Assignments (1)
CONFIRMATORY LICENSE Recorded Aug 17, 2020
From: PURDUE UNIVERSITY
To: NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT
Reel/Frame 053507/0973 →
Continuity (6)
Division 15914293 · Mar 7, 2018
Continuation In Part 14873208 · Oct 2, 2015
Provisional Application 62147267 · Apr 14, 2015
Provisional Application 62075496 · Nov 5, 2014
Provisional Application 62058793 · Oct 2, 2014
Related Publication 20200249221A1 · Aug 6, 2020